1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Mixed Data Cloud Future Of Sunovion's ADHD Drug

 
• By Lucie Ellis-Taitt

Sunovion's ADHD drug, dasotraline, has missed its primary endpoint in a Phase III study in adult patients but has reported mixed results in children, prompting the company to continue pursuing its 2017 plans for an FDA filing in both age groups. But data for the non-stimulant ADHD therapy suggest it will be tricky to overthrow market stalwarts.

Wooden dummy
Sunovion Will Target ADHD As Dasotraline's First Regulatory Filing • Source: Shutterstock

Sunovion Pharmaceuticals Inc. will file its attention deficit hyperactivity disorder (ADHD) drug, dasotraline, this year on the back of mixed data from Phase II and Phase III studies in children and adults – but how well the non-amphetamine-derived stimulant will fair with regulators or against approved ADHD therapies remains unclear.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D